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ABSTRACT
Background: Interstitial cystitis is a clinical syndrome
characterized by symptoms of pelvic pain, urinary ur-
gency and frequency, and nocturia. It can be difficult to
accurately identify interstitial cystitis because the symp-
toms overlap many other common gynecologic and uro-
logic conditions. Patients with undiagnosed interstitial
cystitis may undergo unnecessary procedures, including
hysterectomy.
Methods: A PubMed literature search for articles dating
back to 1990 was conducted on the topics of interstitial
cystitis and hysterectomy. Further references were identi-
fied by cross-referencing the bibliographies in articles of
interest.
Results: The literature review found that hysterectomy is
performed more often in patients with undiagnosed inter-
stitial cystitis than in patients with a confirmed diagnosis.
Interstitial cystitis often coexists with conditions like en-
dometriosis, for which hysterectomy is indicated. Many
patients subsequently diagnosed with interstitial cystitis
continue to experience persistent pelvic pain despite hav-
ing had a hysterectomy for chronic pelvic pain. Careful
history and physical examination can identify the majority
of interstitial cystitis cases.
Conclusion: Interstitial cystitis should be considered
prior to hysterectomy in women who present with pelvic
pain or who experience pelvic pain after a hysterectomy.
If interstitial cystitis is diagnosed, appropriate therapy may
eliminate the need for hysterectomy.
Key Words: Interstitial cystitis, Hysterectomy, Pelvic
pain, Pentosan polysulfate sodium.
INTRODUCTION
Hysterectomy is the second most frequently performed
surgery, after cesarean delivery, among women of repro-
ductive age in the United States. Over 600 000 hysterec-
tomies are performed annually in the United States.1 From
1994 through 1999, 1 in every 9 women aged 35 to 45
years was estimated to have had a hysterectomy.2 The
most frequent indications for hysterectomy during this
time were uterine leiomyoma, endometriosis, and uterine
prolapse.1,2 Chronic pelvic pain (CPP) was the primary
indication for 10% to 12% of all hysterectomies per-
formed.3–5 Although surgery provides some pain relief in
a majority of patients, pain persists in a considerable
proportion of patients.5,6 Hysterectomy for CPP should be
considered after exclusion of other gynecologic and non-
gynecologic diagnoses and after a trial of nonsurgical
treatment.3
Interstitial cystitis (IC) is a clinical syndrome of the bladder
characterized by pelvic pain and urinary urgency and
frequency in the absence of an identifiable cause.7 The
diagnosis of IC is based on history and physical examina-
tion; no definitive test for it exists.8 Diagnosis of IC can be
elusive, because the symptoms of IC are variable and can
mimic those of other urologic and gynecologic condi-
tions.9,10 Patients may experience the symptoms of IC for
years before receiving the correct diagnosis.10 The diffi-
culty in accurately identifying IC may result in unneces-
sary hysterectomies to treat pelvic pain associated with
IC.10,11 In the Interstitial Cystitis Database, 30.5% to 53.5%
of women with IC had undergone a hysterectomy.12 In-
terstitial cystitis should be considered in women who
present with symptoms of CPP, along with dyspareunia
and/or irritative voiding symptoms.13
Hysterectomy and Interstitial Cystitis
Several studies have found a high rate of hysterectomy in
patients subsequently diagnosed with IC. In some cases,
the hysterectomies may have been unnecessary, as the
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SCIENTIFIC PAPERpelvic pain was solely due to IC. In other cases, undiag-
nosed and untreated IC may have coexisted with the
condition that was the indication for hysterectomy. It is
also possible that the hysterectomy itself may have played
a role in precipitating the neurogenic inflammation and
visceral pain associated with IC.14
Driscoll et al10 conducted a retrospective review of 45
patients with IC to determine the presentation and history
of their disease. Patients had been symptomatic for a
median of 5 years before being diagnosed with IC. The
diagnosis of IC was based on National Institute of Diabe-
tes and Digestive and Kidney Diseases (NIDDK) criteria or
by clinical suspicion and a positive potassium sensitivity
test (PST). The initial presentation of IC was highly vari-
able: only 7% of patients presented with simultaneous
symptoms of urinary urgency and frequency, nocturia,
and pain. Most patients (89%) presented with only 1
symptom initially and then progressed to the full spectrum
of symptoms over a mean time of 5 years. Among the 41
women in the study, 14 had received a previous gyneco-
logic diagnosis. Hysterectomy had been performed in 11
patients with a gynecologic diagnosis, including 8 with a
surgical indication of nonspecific pelvic pain.10
Another study looked specifically at the rates of pelvic
surgeries in women with IC by comparing responses from
a survey of 215 IC patients, with 823 women serving as a
community-based control group (both groups, mean age
51 years).15 Women with an established diagnosis of IC
were drawn from a database at a referral center. Diagnosis
of IC was based on NIH criteria, which include positive
cystoscopic findings in addition to symptoms. In this
study, women with IC were twice as likely as controls to
have had a hysterectomy (42.3% vs 21.4%; P0.001).
Although the higher rates of hysterectomies in women
with IC could have been due to a higher prevalence of
concomitant conditions requiring this procedure, it is no-
table that 68.4% of the hysterectomies were done before
the diagnosis of IC, 10.5% were performed in the same
year as the diagnosis of IC, and 21.1% were performed
after the diagnosis of IC.15 The authors concluded that
some of the hysterectomies may have been performed for
an indication of pelvic pain that was in fact due to undi-
agnosed IC.
A third study evaluated 111 women who had persistent or
recurrent pelvic pain after a hysterectomy for CPP.11 This
study was conducted at a large regional CPP center. Pa-
tients were evaluated with a symptom questionnaire, a
physical examination (to identify tenderness at the blad-
der base or anterior vaginal wall), a PST, and optional
cystoscopy with hydrodistention. Irritative voiding symp-
toms were present in 104 (94%) patients, and 88 (79%)
had a positive PST. Of 66 patients who had cystoscopy
with hydrodistention, 61 (92%) had cystoscopic evidence
of IC.
In this study, patients were treated with dietary modifica-
tion alone (n33) or in combination with pentosan poly-
sulfate and/or cystoscopy with hydrodistention (n78).
After 6 months of treatment, the diet-alone group showed
a mean improvement of 15.4% in score on the Pelvic Pain
and Urgency/Frequency (PUF) questionnaire, and the diet
plus other treatment group showed a mean improvement
of 34.2%.11 This study showed that not only was IC diag-
nosed at a high rate among women whose CPP was not
relieved by hysterectomy but also that these patients re-
sponded favorably to treatment for IC.
Another recent study characterized a clinical cohort of 87
women with IC or painful bladder syndrome (PBS) who
were referred to a pelvic pain and sexual-health pro-
gram.16 The diagnosis of IC had been made by board-
certified urologists based on NIDDK criteria. A detailed
history and physical examination were performed for
each patient. The patients had an average of 4.4 previous
pelvic surgeries, with 23% having had 3 surgeries or more.
Almost half (48%) had had a hysterectomy, two-thirds of
which were performed prior to the diagnosis of IC. Pelvic
pain as a comorbidity was reported by 93% of patients.16
The high rate of hysterectomies among women later di-
agnosed with IC may suggest a potential cause of IC.
Pelvic surgeries including hysterectomy may have a neg-
ative effect on the innervation, musculature, or vascula-
ture of the bladder.15 Neural crosstalk between the affer-
ents of irritated or damaged pelvic organs may adversely
affect other organs, perhaps resulting in changes such as
neurogenic inflammation in the secondary organ.14 In the
last study discussed above, 59% of patients reported that
their pain was initiated by a specific event, including
surgery (25%) or a bladder infection (23%), suggesting
that pelvic insults may have played a causative role.16
Even when the indication for hysterectomy (such as en-
dometriosis) is clear, patients may also have IC. Endome-
triosis and IC often coexist in the same patient. In 2
different studies of select groups of patients with CPP
(who exhibited both bladder base and uterine tenderness
[N178] or in whom all other nongynecologic or nonu-
rologic causes had been ruled out [N162]), 75% to 76% of
patients were found to have endometriosis, 82% to 89% had
IC, and 65% to 66% had both conditions concomitantly.17,18
Interstitial cystitis should be considered in any patient who
JSLS (2009)13:350–357 351presents with CPP, even if another condition is diagnosed
that could be partly responsible for the symptoms.11
INTERSTITIAL CYSTITIS
Pathophysiology
The cause of IC is unknown although several potential
mechanisms have been proposed, including abnormal
permeability of the bladder epithelium, neurogenic in-
flammation, an autoimmune or allergic response, and oc-
cult infection. It is likely that several of these factors
interact to produce the clinical picture of IC (Figure
1).19,20 Furthermore, the cause of this condition may not
be the same for all patients.20
A large body of evidence indicates that the symptoms of
IC may be caused by abnormal permeability of the urothe-
lium due to a defect in the glycosaminoglycan (GAG)
layer lining the bladder surface. Abnormalities in the GAG
layer may be causative or the result of poor healing of the
epithelium in patients following an injury to the bladder,
eg, from an infection or pelvic surgery.20 The increased
permeability is thought to allow irritating solutes and tox-
ins, such as potassium from the urine, to contact the
underlying epithelium, triggering the symptoms of pain
and urinary urgency and frequency.21 In response to toxic
stimuli and the resulting pain, mast cells degranulate,
releasing histamine.22 Bladder biopsies from patients with
IC show increased numbers of degranulated mast cells, as
well as increased numbers of substance P-positive nerve
fibers near the mast cells.22,23 The continued inflammation
and nerve-fiber activation can lead to neural upregulation
and hyperalgesia.20 Injury and irritation in one organ can
contribute to hyperalgesia in other organs through vis-
cerovisceral crosstalk.22
Diagnosis
The diagnosis of IC is one of exclusion based on history,
physical examination, laboratory studies, symptom ques-
tionnaires, and other optional tests.8 The NIDDK created
criteria to ensure inclusion of comparable groups of pa-
tients in studies of IC.24,25 These criteria to some extent
became the standard for diagnosis in the clinic.25 Although
the NIDDK criteria clearly identify a subgroup of patients
with IC, they also exclude a substantial proportion of
patients (up to two-thirds) who were clinically diagnosed
with IC.25
In a diagnostic workup for IC, the history should address
the initial presentation and progression of symptoms as
well as any factors that trigger or worsen the symptoms,
such as allergies, certain foods, the menstrual cycle, and
sexual activity.8,26,27 Patients often present initially with
only 1 or 2 mild symptoms then progress over time to the
full symptom complex of urinary urgency and frequency,
nocturia, and pelvic pain.26 Symptoms may occur in a
pattern of flares and remissions.8 The pain caused by IC is
most commonly felt in the suprapubic region but can be
referred to other areas, including other areas of the pelvis
and the thighs.8,26
Symptom questionnaires can help identify the symptoms
of IC for screening and diagnosis. Patients may not report
symptoms such as dyspareunia, because they do not con-
nect it with their urinary symptoms.27 Two commonly
used questionnaires are the PUF questionnaire and the O’
Leary-Sant (OLS) interstitial cystitis symptom and problem
indices (ICSI and ICPI).28,29 Both questionnaires address
the characteristic symptoms of IC as well as the degree of
bother that patients associate with each symptom. The
PUF questionnaire was designed primarily as a clinical
screening tool, whereas the OLS indices were designed for
disease follow-up.8,27
The physical examination in a diagnostic workup for IC
should include a bimanual assessment for pain or tender-
ness at the bladder base or along the urethra. The exam-
ination should assess levator ani tenderness and pelvic
floor dysfunction. Tenderness along the anterior vaginal
wall or at the bladder base can help establish a diagnosis
of IC.8,26,30
Laboratory tests to rule out UTI include urinalysis and
urine culture. Bladder cancer must be ruled out if the
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Figure 1. A proposed model of the etiology of interstitial cysti-
tis.20 Adapted with permission from Evans RJ. Treatment ap-
proaches for interstitial cystitis: multimodality therapy. Rev Urol.
2002;4(suppl 1):S16-S20. GAG  glycosaminoglycan.
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(history of smoking, age 40 years, occupational or other
risk factors).8,31 Cytology of bladder-washing specimens
in combination with cystoscopy is the gold standard for
detection of urothelial neoplasia.32 Cytology of voided
urine samples is less sensitive and should be used as an
adjunct to cystoscopy.33 Noninvasive urine-based immu-
noassays such as the nuclear matrix protein 22 test and the
Bard tumor antigen test may also be used to screen for
bladder cancer; in combination, results from these 2 tests
approach the accuracy of cystoscopy.34 Both tests are
approved by the FDA as an adjunct to but not as a
replacement for cystoscopy.32,33
Several optional tests may aid in the diagnosis of IC.
Urodynamics may be helpful in determining whether de-
trusor instability exists, although this does not rule out the
diagnosis of IC.8,26 Voiding diaries can also be helpful in
identifying frequency, as not all patients recognize their
symptoms of frequency.8
Cystoscopy with hydrodistention is not required for the
diagnosis of IC, except to rule out bladder cancer.31
Among patients with IC, those with positive findings of
cystoscopy (glomerulations or Hunner’s ulcers) are more
likely to have symptoms of IC (although glomerulations
may also be present in women with normal bladders);
however, not all patients with IC will have positive cys-
toscopy.25,35,36
The potassium sensitivity test (PST) identifies patients
with abnormal urothelial permeability by their provoked
response of pain and urgency to intravesical instillation of
potassium.37,38 The PST will be positive in any patient with
increased epithelial permeability of the bladder, including
UTI or radiation cystitis. The PST may be useful to help
identify the bladder as the source of pain.38
A test using intravesical instillation of anesthetics plays a
similar role to that of the PST, but without provoking
symptoms of pain and urgency. Relief of pain following
instillation of a solution of bupivacaine and/or lidocaine
can identify the bladder as the source of pelvic pain in
patients with IC. This test cannot be used in patients
without significant pain, and the lack of a positive result
does not rule out IC as the cause.39
Treatment
Once IC is diagnosed, it is important for the clinician to
counsel the patient and help set treatment expectations.
Patients may feel frustration after years of experiencing
symptoms and not receiving an accurate diagnosis or
effective therapy. A clinician should acknowledge the
patient’s frustration, and reassure her that, once identified,
the condition can be effectively managed. It is important
to let the patient know that it may take several months for
treatment to reach full efficacy and that adherence to the
treatment regimen is crucial to reducing symptoms. Pa-
tients should be educated about the condition as well as
diet and lifestyle changes that can help avoid symptom
flares.40,41
There are several pharmacologic options for the treatment
of IC (Table 1). Pentosan polysulfate sodium (PPS; Elmi-
ron, Ortho-McNeil Janssen Scientific Affairs, LLC, Titus-
ville, NJ) is the only FDA-approved oral agent for the
treatment of IC symptoms and is first-line therapy for most
patients with this condition.41,42 PPS is a heparin-like com-
pound that is thought to act by replenishing the GAG layer
on the bladder surface, thus restoring urothelial imperme-
ability.43 PPS is dosed at 100mg tid. In clinical trials, PPS
was shown to be effective for symptom relief in patients
with IC.44,45 Symptom improvement with PPS is gradual.
Patients should be counseled to stay on PPS therapy for 3
to 6 months to see a clinical response.40 Some patients on
PPS continue to experience improvement in symptom
relief for up to 36 months.46
Other pharmacologic agents (although not FDA-approved
for IC treatment) may be added to PPS as needed for
symptom relief. Antihistamines, such as hydroxyzine, may
be used to reduce mast cell activity,47 and have been
shown to have some efficacy for IC symptom relief, par-
ticularly in patients who are prone to allergies.48 Hy-
droxyzine should be taken at bedtime to minimize seda-
tion side effects at doses up to 75mg/day.40
Tricyclic antidepressants (TCAs), such as amitriptyline,
also benefit many patients with IC.49,50 These drugs have
mild antihistamine, analgesic, and anticholinergic effects,
and are widely used in the treatment of neuropathic pain
because of their effects on CNS pain transmission.51 In
addition, TCAs may help improve sleep because of their
sedative effect.20 Anticholinergic side effects like dry
mouth occur in the majority of patients and may lead to
treatment discontinuation for some patients.49,50 Careful
dosing (25mg/day to 50mg/day at bedtime) can minimize
these side effects.27,50
Anticonvulsants, such as gabapentin and pregablin, have
been used to treat neuropathic pain51 and may be of
benefit for IC patients with severe pain.20,52 Gabapentin
should be dosed from 300mg/day to 2400mg/day and
requires careful dose titration.20
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combination with oral agents.20 Cocktails consisting of a
local anesthetic (bupivacaine or alkalinized lidocaine) and
heparin (as a bladder surface coating agent) may be ad-
ministered as initial therapy while oral agents take effect
or can be used for treatment of symptom flares.53,54 Di-
methyl sulfoxide (DMSO) is approved by the FDA as an
intravesical agent for the relief of IC symptoms.55 DMSO
has both anti-inflammatory and analgesic properties.56
In addition to pharmacologic agents, nonpharmacologic
approaches to therapy can provide symptom relief for
patients with IC. Every patient with IC should be coun-
seled about dietary and lifestyle changes that can mini-
mize symptom flares. A range of foods have been associ-
ated with symptom flares, particularly foods or drinks that
contain caffeine or alcohol, are spicy, or have a low pH.
Patients may already be aware of some of their “triggers”;
use of a diary can help track others.57 Symptom flares are
also associated with stress, which patients can reduce by
using stress-reduction techniques.57 For patients who ex-
perience dyspareunia, use of lubricants, lidocaine jelly, or
premedicating with antispasmodics or muscle relaxants
can reduce pain during sex.58
Bladder training is an option to reduce urination fre-
quency in patients who experience only mild pain on
bladder filling. The patient slowly lengthens the intervals
between voids, increasing the interval by up to 15 minutes
every week.57,59
High-tone pelvic floor dysfunction (PFD) involving pelvic
floor muscle tenderness and spasm is commonly found in
patients with IC.60 Patients with high-tone PFD respond
favorably to physical therapy, including realignment of
the sacrum and ilium, myofascial release, and overall
strengthening and stretching.61 Internal (Thiele) massage
can be effective for the relief of IC symptoms in patients
with high-tone PFD or in patients who have not re-
sponded to medical therapy.60,62
For patients who do not respond to pharmacologic and
behavioral therapies, sacral neuromodulation has been
shown to be beneficial in several studies, with improve-
ments in pain and urinary-symptom scores, as well as
decreased need for narcotics.63–66
Patients should be reevaluated 1 month to 3 months after
therapy is initiated and therapy adjusted as needed.40,41
Further follow-up visits should occur at 3-month to
Table 1.
Pharmacologic Therapies for Interstitial Cystitis
20,27,42,54,56,67
Agent MOA Dose Side Effects
Oral
PPS* May repair GAG layer on urothelial
surface, restoring impermeability
100 mg tid Hair loss, GI upset, headache,
rash
Hydroxyzine Controls allergic response and mast
cell activation
10 to 25 mg/day qd at bedtime
Increase up to 100 mg/day
during allergy season
Drowsiness, dry mouth
Amitriptyline Inhibits neural activation, also
analgesic, anticholinergic
10 to 50 mg/day qd at bedtime Dizziness, dry mouth, drowsiness,
weight gain, nausea
Gabapentin Unknown Up to 2400 mg/day qd at
bedtime
Dizziness, somnolence, nausea,
edema
Oxycodone Control of severe pain 5 to 10 mg every 4 h prn GI upset, somnolence
Intravesical
DMSO Anti-inflammatory, analgesic,
muscle relaxant
50 cc 50% qw for 6 weeks Worsening of IC symptoms,
garlic-like taste and breath odor
Anesthetics† Control of pain 0.5% bupivacaine; 2% alkalinized
lidocaine prn
Postinstillation pain; urinary
retention
Heparin† May help restore mucous layer 10 to 40,000 IU/day in 10 mL
water
qd to qw
Postinstillation pain
*PPS  pentosan polysulfate sodium; DMSO  dimethyl sulfoxide.
†May be used in combination with each other.
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physician as soon as possible when symptom flares occur
and can be treated immediately with intravesical instilla-
tion of an anesthetic cocktail.41
CONCLUSION
Hysterectomies may be performed unnecessarily in
women with IC. Clinicians should consider all sources of
pelvic pain before performing a hysterectomy for the
primary indication of CPP. Patients with documented en-
dometriosis may still have concomitant IC and should be
evaluated and treated for IC prior to hysterectomy. With
the appropriate diagnostic tools, IC can be identified early
in the progression of the disease. An individualized, mul-
timodal approach to treatment—including both pharma-
cologic and nonpharmacologic therapies—can provide
symptom relief in the majority of patients with IC.
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